Provided by Tiger Trade Technology Pte. Ltd.

Novo-Nordisk A/S

37.59
+0.19000.51%
Volume:2.98M
Turnover:111.87M
Market Cap:167.84B
PE:9.39
High:37.65
Open:37.64
Low:37.28
Close:37.40
52wk High:64.16
52wk Low:35.12
Shares:4.47B
Float Shares:3.19B
Volume Ratio:1.21
T/O Rate:0.09%
Dividend:1.79
Dividend Rate:4.75%
EPS(TTM):4.00
EPS(LYR):3.62
ROE:59.82%
ROA:18.73%
PB:5.15
PE(LYR):10.38

Loading ...

Novo Nordisk Aims for $23 Billion in 2035 Pipeline Sales

MT Newswires Live
·
Sep 21

Novo Nordisk Stock Tumbles as Ozempic Maker Sets Out 2030 Goals

Dow Jones
·
Sep 21

Wegovy Maker Novo Nordisk Targets Several New Blockbuster Drugs in Coming Years

Dow Jones
·
Sep 21

Novo Unveils Ambitious Pipeline Plans, Yet Shares Slide 6% as Investors Seek More

Trading Random
·
Sep 21

Eli Lilly, Novo sued over risk of sudden vision loss, WSJ reports

TIPRANKS
·
Sep 20

Novo Nordisk’s Once-Weekly Insulin Study Signals a New Phase for Diabetes Care

TIPRANKS
·
Sep 19

Novo Nordisk A/S Series B Stock Rises Friday, Outperforms Market

Dow Jones
·
Sep 19

Novo Nordisk's Sogroya Gets Positive EU Opinion for Children With Idiopathic Short Stature

MT Newswires Live
·
Sep 18

Sandoz Faces Uncertain Opportunity with New Drug Approval in Canada

Dow Jones
·
Sep 18

Sandoz Receives Marketing Authorization for Generic Version of Ozempic in Canada

MT Newswires Live
·
Sep 18

When Weight Loss Isn't the Goal of Taking a GLP-1

Dow Jones
·
Sep 18

Novo Nordisk Wins EMA Panel Backing for New Haemophilia A Therapy FREHEMGO

TIPRANKS
·
Sep 18

Novo Nordisk A/S Stock (NVO) Moved Up by 3.02% on Sep 17: What Signal Does It Send?

TradingKey
·
Sep 18

Cboe data suggests bullish flow in Novo Nordisk with shares up 3.3%

TIPRANKS
·
Sep 17

Novo Nordisk's Frehemgo to Treat Haemophilia A Receives CHMP Recommendation for EU Approval

MT Newswires Live
·
Sep 17

Novo Nordisk reports CHMP adopts positive opinion on MAA for Frehemgo

TIPRANKS
·
Sep 17

Movement Alert|Novo-Nordisk A/S Rises 3.07% in Regular Trading, Partners With Orbis Medicines on $1.4 Billion AI Drug Discovery Deal

Market Focus
·
Sep 17

Novo Nordisk: Market Perform and $47 Price Target Maintained Amid Obesity Strength and Competitive Risks

TIPRANKS
·
Sep 17

Novo Nordisk announces FRONTIER5 Phase 3b results for denecimig

TIPRANKS
·
Sep 17

Novo, Orbis Sign up to $1.4 Billion Deal to Develop Oral Drugs

Reuters
·
Sep 17